Clinical Trial

A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, Phase 2 clinical trial to evaluate the efficacy and safety, PK and immunogenicity of SHR-A1904 in patients with advanced or metastatic biliary tract cancer (BTC). Patients will treat with SHR-A1904 until unacceptable toxicity or disease progression.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-01
Trial Details
NCT Number NCT07450976
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Biliary Tract Cancer
Enrollment 151 participants
Start Date 2026-03-25
Primary Completion 2030-12 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-31